Want to see IN:KRONOX full AI Analyst Report?
Top Page
Kronox Lab Sciences Limited
(KRONOX)
Select Model
Select Model
Rating:77Outperform
Price Target:
₹183.00
▲(37.40% Upside)
Action:Reiterated
Date:07/02/26
The score is driven primarily by strong financial performance (high profitability and very low leverage), supported by an upward technical trend. The main constraints are weaker latest-year cash flow and a valuation profile that is not particularly cheap with a low dividend yield.
Positive Factors
High profitability & margins
Sustained high gross, EBIT and net margins alongside rising net income indicate structural pricing power and operating efficiency. These margin levels support durable cash generation, reinvestment capacity and resilience to input cost swings over the medium term.
Negative Factors
Declining cash flow in latest year
A notable year-over-year drop in operating and free cash flow signals possible working capital strain or higher investments. If the decline persists, it could constrain reinvestment, dividend capacity or force greater reliance on external funding, weakening financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability & margins
Sustained high gross, EBIT and net margins alongside rising net income indicate structural pricing power and operating efficiency. These margin levels support durable cash generation, reinvestment capacity and resilience to input cost swings over the medium term.
Read all positive factors
Kronox Lab Sciences Limited (KRONOX) vs. iShares MSCI India ETF (INDA)
Market Cap
₹6.00B
Dividend Yield0.35%
Average Volume (3M)4.31K
Price to Earnings (P/E)21.6
Beta (1Y)1.37
Revenue Growth1.02%
EPS Growth8.50%
CountryIN
Employees70
SectorHealthcare
Sector Strength45
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)3.53
Shares Outstanding37,104,000
10 Day Avg. Volume5,373
30 Day Avg. Volume4,310
Financial Highlights & Ratios
PEG Ratio1.86
Price to Book (P/B)3.65
Price to Sales (P/S)4.19
P/FCF Ratio20.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kronox Lab Sciences Limited Business Overview & Revenue Model
Company Description
Kronox Lab Sciences Ltd. operates as a manufacturer and global supplier of a diverse range of chemical products, encompassing fine chemicals, inorganic compounds, phosphates, and metallic chemicals, serving markets both within India and worldwide....
How the Company Makes Money
null...
Kronox Lab Sciences Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
83
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 516.64M | 1.01B | 1.00B |
| Gross Profit | 259.24M | 546.44M | 492.71M |
| EBITDA | 183.52M | 394.65M | 356.53M |
| Net Income | 129.91M | 276.60M | 254.67M |
Balance Sheet | |||
| Total Assets | 1.13B | 1.28B | 988.26M |
| Cash, Cash Equivalents and Short-Term Investments | 521.69M | 487.41M | 358.73M |
| Total Debt | 26.14M | 16.07M | 0.00 |
| Total Liabilities | 112.75M | 113.96M | 87.22M |
| Stockholders Equity | 1.01B | 1.16B | 901.05M |
Cash Flow | |||
| Free Cash Flow | 230.30M | 205.85M | 275.92M |
| Operating Cash Flow | 269.08M | 238.93M | 306.97M |
| Investing Cash Flow | -271.70M | -238.20M | -283.94M |
| Financing Cash Flow | 7.62M | -3.62M | -18.54M |
Kronox Lab Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹6.00B | 21.61 | ― | 0.35% | 1.02% | 8.50% | |
66 Neutral | ₹2.50B | 19.52 | ― | 1.11% | -39.14% | -65.07% | |
61 Neutral | ₹4.78B | 24.64 | ― | 0.82% | 3.24% | 6.11% | |
61 Neutral | ₹4.68B | 18.48 | ― | ― | 17.46% | 101.58% | |
59 Neutral | ₹2.60B | 17.75 | ― | 1.49% | 1.73% | -35.32% | |
56 Neutral | ₹2.91B | 15.76 | ― | 0.56% | -4.78% | -5.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KRONOX
Kronox Lab Sciences Limited
161.65
-33.33
-17.09%
IN:ASAHISONG
Asahi Songwon Colors Ltd.
247.05
-185.89
-42.94%
IN:CHEMBOND
Chembond Chemicals Limited
186.00
-38.47
-17.14%
IN:DICIND
DIC India Limited
520.95
-106.61
-16.99%
IN:MANORG
Mangalam Organics Ltd
546.00
-28.80
-5.01%
IN:PODDARMENT
Poddar Pigments Limited
245.00
-62.94
-20.44%
Kronox Lab Sciences Limited Corporate Events
Kronox Lab Sciences to Close Trading Window Ahead of Q1 Results
Jun 25, 2026
Kronox Lab Sciences Limited has announced that its trading window for dealing in the company’s equity shares will be closed for all designated persons starting 1 July 2026, in line with SEBI’s Prohibition of Insider Trading Regulations...
Kronox Lab Sciences Publishes Audited FY26 Results in Newspapers
May 24, 2026
Kronox Lab Sciences Limited has published its audited financial results for the quarter and full year ended 31 March 2026 in leading English and Gujarati newspapers, in line with SEBI’s listing and disclosure regulations. By formally notifyi...
Kronox Lab Sciences Denies Role in Sharp Share Price Movement
Apr 8, 2026
Kronox Lab Sciences Limited has responded to recent sharp movements in its share price after queries from the National Stock Exchange of India and BSE, stating that it has consistently disclosed all material and price-sensitive information in line...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.